The use of recombinant factor VIIa in the treatment of bleeding disorders.
about
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaIneffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleedingClinical review: Traumatic brain injury in patients receiving antiplatelet medicationSCT in Jehovah's Witnesses: the bloodless transplantSuccessful recovery after an overdose of argatroban.Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital recordsTreatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXFactor VIIa interaction with endothelial cells and endothelial cell protein C receptor.Rare case of acquired haemophilia and lupus anticoagulant.Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature.Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection.Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study.Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settingsRecombinant Activated Factor VII Significantly Reduces Transfusion Requirements in Cardiothoracic Surgery.Recombinant factor VIIa in the treatment of non-hemophiliac bleeding.Endpoints in clinical trials involving hemostasis and bleeding in patients with hemophilia.Recombinant factor VIIa: use in fatal post partum hemorrhage - Indian experience case series and review of literature.Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.Management of bleeding emergencies: when to use recombinant activated factor VII.Prevention of intraventricular haemorrhage: a role for recombinant activated factor VII?Basic aspects of bypassing agents.Advances in hemorrhagic stroke therapy: conventional and novel approaches.Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicityTherapeutic management of acute intracerebral haemorrhage.International recommendations on the diagnosis and treatment of patients with acquired hemophilia ARecombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.Historical perspective and future direction of coagulation research.Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage.Reversal of antithrombotic agents.Recombinant Factor VIIa for Bleeding in Non-hemophiliac Pediatric Patients.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.Acute management of bleeding in patients on novel oral anticoagulants.Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®))Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review.Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
P2860
Q24201292-C31B5B5E-7C0A-436D-B981-371DDDCA9D84Q24236583-D17B5D8F-8304-4BF2-9B71-1388B0BC0D7EQ24245204-5D589032-8531-4A6D-884A-801D26CCEDD1Q25256556-954DD35D-EC56-49C1-A40F-BCB76A4DF324Q26830409-1F2BC83E-BDAD-461F-A62E-4FA7DB94D77BQ28267204-25FF440F-A692-4CA4-B6DB-394E2B5CA871Q33370151-0E99BE70-D078-4471-9A29-F3A40CCF37D1Q33394197-A9225D21-905D-4E5E-87D0-4D048CB537E4Q33571590-F84EB2A9-9C84-48F3-B0F9-AAC7215EBA9DQ33608230-C45AC726-3D6B-4F50-BE53-26A048C8ED6CQ33729380-151FDE5E-CC9D-43E6-87BC-71BEBBE4A2A3Q33969541-8D652D33-D4B5-4B27-BDD4-4C1B83F7DCABQ34101751-A18C436E-B0A2-45CE-A961-0FD0062F0AD8Q34707273-6F88D79A-D6CA-4021-AEDF-02F6DC76A454Q34786006-EF04044A-737F-438A-892C-A3976FE94D83Q35578941-962D2105-7C10-444C-9BC8-4C7DFECFDC01Q35807333-48C8A6BD-76BF-4EBD-AA4A-73BDC10D47D5Q36077574-593E21C7-D5A5-4A40-8339-969CFD3B98B3Q36179821-5A6E35E1-0A97-4679-B211-7F9D5368E288Q36263910-294E29F0-6A22-4522-A496-38750A04D9CBQ36284640-6EE79F57-5340-4A3F-918E-E7E47C0B59AAQ36349585-7B5477E1-24C5-4BCD-8C3B-ED6423A97B71Q36493713-07E26310-8905-424E-ACDD-82A074CF7EFAQ36661832-4D7E0414-B5A1-4DF6-86E7-A8B3B8BB721AQ36944012-9210A386-F198-4F65-BE4F-53B6E0C00052Q36945945-C7260AC2-1F50-4FFB-B2B3-B866578900ADQ36950922-7E444DD0-B52D-4AA8-973A-AB185B99825CQ37013014-6B493769-65CB-4888-865D-C4C561DDAEDCQ37146064-FA2B9A22-8277-458B-AC23-5F1B444FB138Q37710241-AFA3A74B-A8AC-48D9-A3C5-5BC4E3B3505AQ37778292-8C4253E2-509A-41E2-8B8F-EB0DC1D4B6A6Q37903961-792B89E5-9876-45BA-AB54-6EE0D57FDDF6Q37978627-D135D011-7DC7-40AF-B6F8-45348B1521C1Q37998377-DA1420D5-AFBE-454D-82C1-742C64292E54Q38051320-5A272052-8FA8-40E9-8E5F-E344910B917EQ38060224-73AEB60D-7D3D-40DF-8598-01E1D4302BC3Q38065699-5939E7BB-8C21-4FAE-9145-1921E2FB85D6Q38091658-04ECA339-695B-4DC9-BED7-4769130B152DQ38128719-8AD11208-C4C7-41AC-B6F8-06673AF1402CQ38282775-51CE8262-26A4-4A05-88EE-F78D417D0EC4
P2860
The use of recombinant factor VIIa in the treatment of bleeding disorders.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The use of recombinant factor VIIa in the treatment of bleeding disorders.
@ast
The use of recombinant factor VIIa in the treatment of bleeding disorders.
@en
The use of recombinant factor VIIa in the treatment of bleeding disorders.
@nl
type
label
The use of recombinant factor VIIa in the treatment of bleeding disorders.
@ast
The use of recombinant factor VIIa in the treatment of bleeding disorders.
@en
The use of recombinant factor VIIa in the treatment of bleeding disorders.
@nl
prefLabel
The use of recombinant factor VIIa in the treatment of bleeding disorders.
@ast
The use of recombinant factor VIIa in the treatment of bleeding disorders.
@en
The use of recombinant factor VIIa in the treatment of bleeding disorders.
@nl
P1433
P1476
The use of recombinant factor VIIa in the treatment of bleeding disorders
@en
P2093
Gilbert C White
Harold R Roberts
P304
P356
10.1182/BLOOD-2004-06-2223
P407
P577
2004-08-24T00:00:00Z